Outset Medical, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 690145107 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
PFM Health Sciences, LP 13G/A Amendment 1	2.9%	530,796	13G/A Amendment 1	2/17/2026 Event 12/31/2025
PFM Health Sciences, LP	2.9%	530,796
PFM Health Sciences GP, LLC	2.9%	530,796
PFM Healthcare Growth Equity I GP, LLC	2.9%	530,796
Partner Asset Management, LLC	2.9%	530,796
Brian D. Grossman	2.9%	530,796
Alyeska Investment Group, L.P. 13G	9.6%	1,703,083	13G	5/15/2025 Event 3/31/2025
Alyeska Investment Group, L.P.	9.6%	1,703,083
Alyeska Fund GP, LLC	9.6%	1,703,083
Anand Parekh	9.6%	1,703,083
PFM Health Sciences, LP 13G	9.4%	25,000,000	13G	3/17/2025 Event 3/10/2025
PFM Health Sciences, LP	9.4%	25,000,000
PFM Health Sciences GP, LLC	9.4%	25,000,000
PFM Healthcare Growth Equity I GP, LLC	3.8%	10,000,000
Partner Asset Management, LLC	9.4%	25,000,000
Brian D. Grossman	9.4%	25,000,000
Perceptive Advisors LLC 13G	9.5%	5,625,000	13G	2/28/2025 Event 1/8/2025
Perceptive Advisors LLC	9.5%	5,625,000
Joseph Edelman	9.5%	5,625,000
Perceptive Credit Advisors LLC	9.5%	5,625,000
Perceptive Credit Holdings IV, LP	9.5%	5,625,000
FMR LLC 13G/A Amendment 6	7.0%	3,671,213	13G/A Amendment 6	2/12/2025 Event 12/31/2024
FMR LLC	7.0%	3,671,213
Abigail P. Johnson	7.0%	3,671,213
Vanguard Group Inc 13G/A Amendment 5	4.96%	2,608,902	13G/A Amendment 5	1/31/2025 Event 12/31/2024
Durable Capital Partners LP 13G	9.9%	26,609,101	13G	1/10/2025 Event 1/3/2025

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q1	2	99.4 k	$389 k	$0
2025 Q4	3	197 k	$738 k	$0
2025 Q3	3	177 k	$2.50 M	$0
2025 Q2	2	34.7 k	$668 k	$0
2025 Q1	2	24.6 k	$272 k	$0
2024 Q4	80	21.4 M	$23.8 M	$116 k
2024 Q3	87	26.1 M	$17.6 M	$86.2 k
2024 Q2	131	55.5 M	$214 M	$602 k
2024 Q1	122	61.6 M	$138 M	$212 k
2023 Q4	149	62.1 M	$336 M	$1.67 M
2023 Q3	158	53.8 M	$584 M	$1.41 M
2023 Q2	160	53.0 M	$1.16 B	$763 k
2023 Q1	169	52.0 M	$958 M	$1.03 M
2022 Q4	162	50.2 M	$1.30 B	$563 k
2022 Q3	143	47.8 M	$760 M	$2.00 M
2022 Q2	156	48.5 M	$721 M	$2.66 M
2022 Q1	166	51.4 M	$2.33 B	$11.9 M
2021 Q4	167	50.4 M	$2.32 B	$11.6 M
2021 Q3	149	50.7 M	$2.51 B	$4.94 M
2021 Q2	132	48.7 M	$2.43 B	$0
2021 Q1	113	40.8 M	$2.22 B	$0
2020 Q4	112	37.4 M	$2.09 B	$0
2020 Q3	87	36.2 M	$1.76 B	$0